关于DPP9 rs2109069和IFNAR2 rs2236757多态体与COVID-19死亡率之间的相关性的研究
Mahnaz Safari1, Rezvan Tavakoli2, Mohammadreza Aghasadeghi2,3
1Department of Biology, East Tehran Branch, Islamic Azad University, Tehran, Iran.
Nucleosides, nucleotides & nucleic acids
|April 25, 2024
概括
双二酶9 (DPP9) 和干扰素α和β受体亚单元2 (IFNAR2) 基因中的遗传变异会影响COVID-19的严重程度. IFNAR2 A基因组与较轻的疾病相关,而DPP9 A基因组与增加的死亡率有关.
科学领域:
- 免疫遗传学 免疫遗传学
- 分子生物学分子生物学
- 传染病研究 传染病研究
背景情况:
- COVID-19的严重程度受到免疫系统的炎症反应的影响.
- 细胞因子和化学因子基因多态可能在COVID-19结果中发挥作用.
研究的目的:
- 研究DPP9和IFNAR2基因中的单核酸多态 (SNPs) 与COVID-19严重程度之间的关联.
- 为了确定特定的遗传变异是否与COVID-19患者的疾病结果相关.
主要方法:
- 使用的聚合酶连锁反应与限制片长多态化 (PCR-RFLP) 试验.
- 分析了954名COVID-19患者 (528人康复,426人死亡).
- 在IFNAR2 (rs2236757) 和DPP9 (rs2109069) 中检查的多态.
主要成果:
- IFNAR2 rs2236757 A等位基因与COVID-19严重程度的降低有关.
- 与已康复患者相比,已死亡患者的DPP9 rs2109069 A等位基因频率更高.
- 携带DPP9 G等位基因和IFNAR2 A等位基因与明显更好的疾病恢复相关.
结论:
- IFNAR2 rs2236757 一个等位基因与COVID-19严重程度的降低有关.
- DPP9 rs2109069 一个等位基因的频率在非幸存者中更高,这表明在COVID-19死亡率中发挥了作用.
- 炎症反应基因的遗传变异,如DPP9和IFNAR2,对于确定COVID-19的严重程度至关重要.
更多相关视频
05:53Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry
Published on: June 21, 2018
10.1K
10:21Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma
Published on: September 20, 2024
422
相关概念视频
01:05Single Nucleotide Polymorphisms-SNPs
A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...